Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Itepekimab in Chronic Rhinosinusitis With Nasal Polyps
NCT06834360Phase 3Active, not recruiting
- Sponsor
- Sanofi
- Start
- Feb 2025
- Primary completion
- Sep 2026
- Modality
- Monoclonal Antibodies
- Countries
- 23
01
Overview
A Phase 3 trial of itepekimab in chronic rhinosinusitis with nasal polyps (CRSwNP), sponsored by Sanofi. Started Feb 2025; status: active, not recruiting.
02
Drugs
itepekimab
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on NCT06834360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06834360.